UNITY Biotechnology Announces Publication In NEJM Article Titled, "Safety And Efficacy Of Senolytic UBX1325 In Diabetic Macular Edema," Evidence Highlighting The Potential Of Senolytic Therapeutics To Provide Long-Term Improvements In Vision In Diabetic Macular Edema

Author: Benzinga Newsdesk | April 23, 2025 08:08am

UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the peer-reviewed journal NEJM Evidence published results from the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). As reported in the article titled, "Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema," the results suggested that the selective clearance of senescent cells in the retina provided disease-modifying and long-lasting improvements in vision in patients with DME, supporting the potential of UBX1325 as a novel modality for retinal diseases.

Posted In: UBX